In this systematic review and meta-analysis, TP53 oncogenic somatic variants were associated with decreased 1-year survival rates in glioblastoma patients; however, no significant correlations were found with overall survival, 2-year mortality, or progression-free survival. This evidence concerns the gene TP53 and glioblastoma.